North American Thyroid Cancer Survivorship Study (NATCSS)


North American Thyroid Cancer Survivorship Study (NATCSS): A Multicenter Quality of Life Study

The incidence of thyroid cancer has increased substantially in the past several decades and is estimated to become the 3rd most common cancer in women of all ages and the 2nd most common cancer in women under age of 45 by 2019. With 5-year and 10-year survival rates reaching 95%, a relatively younger age at diagnosis, and a rising incidence of disease, a greater prevalence of thyroid cancer survivors is emerging. This study is a multi-institutional study led by the University of Chicago to understand the quality of life of thyroid cancer survivors and elucidate common challenges and issues faced by this population of patients. 

This protocol establishes a multicenter thyroid cancer survivirship cohort; it does not dictate treatment or interventions. Columbia University Medical Center (CUMC) will serve as a collaborating institution in conjunction with the University of Chicago to confer a better understanding of how thyroid cancer changes the QoL of survivors and identify the areas of impact. 

Are you Eligible? (Inclusion Criteria)

Inclusion: Thyroid cancer cases (any histologic type)

  • Males or females, 18 years or older.

All persons recruited will be able to read English. We will be recruiting participants who have incident TC as well as participants diagnosed many years prior to the initiation of our study. 

Specialty Area(s)

Trial Location

Columbia University Medical Center
HIP (The Herbert Irving Pavilion)
8th Floor
New York, NY 10032
United States